Clinical abuse potential study - MORPHABOND ER VS MS CONTIN

Clinical abuse potential study

If Manipulated and Taken Intranasally, MORPHABOND ER Was Significantly Less Liked vs MS Contin

®1,2

 

Mean Drug Liking Over Time

  • In the primary endpoint of mean maximum Drug Liking (Emax), scores for crushed intranasal MORPHABOND ER were significantly lower than crushed intranasal MS Contin® (71.7 vs 85.3 [P<0.0001])

76%

of subjects (n=19) experienced a reduction in Drug Liking with crushed intranasal MORPHABOND ER vs crushed intranasal MS Contin®

If Manipulated and Taken Intranasally, Subjects Were Less Willing to Take MORPHABOND ER Again vs MS Contin®1

Mean Take Drug Again

Abuse of MORPHABOND ER is still possible by intranasal, intravenous, and oral routes
Abuse of MORPHABOND ER is still possible by intranasal, intravenous, and oral routes

Study design: The intranasal abuse potential and relative bioavailability of MORPHABOND ER was evaluated in a randomized, double-blind, double-dummy, placebo-controlled, single-dose, 4-way crossover study in 25 nondependent recreational opioid users comparing crushed intranasal MORPHABOND ER 60 mg, crushed intranasal MS Contin® 60 mg, and intact oral MORPHABOND ER 60 mg.

  • Primary endpoint: mean maximum effect (Emax) for Drug Liking between crushed intranasal MORPHABOND ER and crushed intranasal MS Contin®
  • Secondary comparisons for the primary endpoint included Emax for intact oral MORPHABOND ER compared with crushed intranasal MS Contin® and crushed intranasal MORPHABOND ER
  • Other secondary endpoints included Take Drug Again assessments and determining the relative bioavailability of morphine in plasma for crushed intranasal and intact oral MORPHABOND ER compared with crushed intranasal MS Contin®
  • Drug Liking (primary) and Take Drug Again (secondary) endpoints were measured on a 100-mm bipolar visual analog scale (VAS) where 50 represents a neutral response, 0 represents the strongest negative response, and 100 represents the strongest positive response

Page navigation - Intranasal Morphabond ER vs MS Cotin

Why Abuse-Deterrent Formulations

Prescription opioid abuse continues to grow. Abuse-deterrent formulations are just one potential solution to this complex
societal problem

The MORPHABOND ER Savings Program

Eligible commercially insured patients may pay as little as $10 a month
Please see Eligibility Criteria and Terms and Conditions below.

MORPHABOND ER Dosing

MORPHABOND ER has a 1-to-1 conversion from MS Contin®